Skip to main content
PMC home page
Oncotarget logoLink to Oncotarget
. 2017 Jul 11;8(59):100490–100498. doi: 10.18632/oncotarget.19162

Prognostic role of long noncoding RNA ZFAS1 in cancer patients: a systematic review and meta-analysis

Tian Lan 1,*, Xiong Lan 2,*, Guangcai Li 2, Zhen Zheng 2, Minghua Zhang 2, Faxiang Qin 2
PMCID: PMC5725037  PMID: 29245995

Abstract

Long noncoding RNA ZFAS1 has been identified as a crucial role in the tumorigenesis of malignant tumors. Numerous studies reported that the expression levels of ZFAS1 in tumor tissues were dramatically higher than that in adjacent normal tissues. We conducted a meta-analysis to investigate the correlation between ZFAS1 expression and clinical outcomes of cancer patients. The databases of PubMed, EMBASE, Web of Science, Cochrane Library, CNKI and WanFang were retrieved for eligible studies. A total of 841 patients from 9 studies were eventually included. Our results demonstrated that increased ZFAS1 expression was significantly associated with poor OS in cancer patients (HR = 2.13, 95% CI = 1.71–2.65, P < 0.001). Patients with high ZFAS1 expression presented shorter RFS than those with low ZFAS1 expression (HR = 2.00, 95% CI = 1.45–2.77, P < 0.001). The clinicopathological parameters analysis demonstrated that increased ZFAS1 expression was significantly associated with vascular invasion (OR = 2.26, 95% CI = 1.36–3.78, P = 0.002), lymph node metastasis (OR = 2.98, 95% CI = 2.12–4.19, P < 0.001) and advanced TNM stage (OR = 3.00, 95% CI = 2.18–4.12, P < 0.001). In conclusion, lncRNA ZFAS1 might serve as a prognostic biomarker for cancer patients and increased ZFAS1 expression may be closely related to advanced characteristics of cancer.

Keywords: lncRNA, ZFAS1, cancer, prognosis, meta-analysis

INTRODUCTION

As one of the most serious diseases wreaking havoc on human health, cancer has now served as the leading cause of morbidity and mortality in most areas worldwide [1]. Since early diagnosis greatly affect the survival rate of cancer patients and the prognosis of various cancers remains very poor, accumulating researchers are attempting to identify the key biological factors involved in the development and progression of this fatal disease [2]. Nevertheless, few molecular targets have been deemed as biomarkers for diagnosis and prognosis in clinical application. Therefore, identifying reliably diagnostic and prognostic markers for cancer is urgently needed. Nowadays, an increasing number of studies reported the role of non-coding RNAs (ncRNAs) in cancer, including long noncoding RNA (lncRNAs), micro-RNAs (miRNAs) and small nucleolar RNAs (snoRNAs) [3–5].

Long noncoding RNAs (lncRNAs) are a class of RNA molecule with more than 200 nucleotides in length and do not code for proteins but bear the ability to increase and/or decrease the gene expressions3. Accumulating evidence showed that lncRNAs have been identified to activate and/or inhibit multiple biological regulatory processes, including development, differentiation and carcinogenesis [6, 7]. As a newly identified lncRNA, zinc finger antisense 1 (ZFAS1) has been found in different cancers, including breast cancer, colorectal cancer (CRC), gastric cancer (GC) and hepatocellular carcinoma (HCC) [8, 9]. More importantly, the dysregulation of ZFAS1 was closely related to cell cycle control and apoptosis of cancer cells [10]. However, most studies investigating the implications of ZFAS1 expression are limited by small sample size. In addition, no systematic review or meta-analysis has been performed to assess the association between ZFAS1 expression and the prognosis of patients with cancers. Thus, we conducted a systematic review and meta-analysis to explore the prognostic role of ZFAS1 in cancers patients.

MATERIALS AND METHODS

Literature search strategies

An electronic search was performed in PubMed, EMBASE, Web of Science, Cochrane Library as well as Chinese databases including CNKI and WanFang database for all the relevant studies which reported the association between lncRNA ZFAS1 expression and clinical outcomes in different cancers by utilizing the following search strings: “long non-coding RNA ZFAS1” or “lncRNA ZFAS1” or “ZFAS1” or “Zinc finger antisense 1”, “cancer or carcinoma or tumor or neoplasm”, and “pathology”. These terms were used in different combinations. No limitation was placed on publication status or language.

Inclusion and exclusion criteria

The eligible studies met the following criteria: (1) any kind of human cancer was studied; (2) the study provided at least one of following clinical outcomes: gender, tumor size, vascular invasion (VI), lymph node metastasis (LNM), TNM stage, recurrence-free survival (RFS) and overall survival (OS); (3) the method of detecting lncRNA ZFAS1 was restricted to quantitative real-time reverse transcription polymerase chain reaction (qRT-PCR); (4) patients were divided into high and low groups based on the expression levels of ZFAS1. Exclusion criteria were as follows: (1) reviews, case reports, meta-analysis, and duplicate publications; (2) the studies without usable data; (3) the studies only focusing on the molecular mechanism of lncRNA ZFAS1.

Data extraction and quality assessment

Two investigators independently extracted the data from each original publication including first author’s name, year of publication, country of origin, cancer type, total cases, numbers of patients in high and low ZFAS1 expression groups, the detection method, outcome measures and the cut-off value for ZFAS1 levels. Missing information was estimated according to the Cochrane Handbook and was requested from the authors of original studies if necessary. Discrepancies between the 2 investigators were resolved by discussion and consensus. The quality of included studies was assessed via using Newcastle-Ottawa Scale (NOS) standard [11], which includes selection (4 points), comparability (2 points) and outcome (3 points) with a score range of 0∼9. A study with NOS score more than 6 was considered to be of high quality.

Statistical analysis

Odds ratios (ORs) with 95% confidence intervals (CIs) were estimated to evaluate the correlation between ZFAS1 expression and the clinical outcomes in cancer patients. According to the American Joint Committee on Cancer (AJCC) staging system [12], TNM stage was separated into two groups, which were early stage (I–II) and advanced stage (III–IV). Additionally, lymph node metastasis (LNM) was divided into “positive” and “negative” groups. Statistical analysis was performed by utilizing RevMan 5.3 software and Stata SE12.0 (Stata Corporation). Cochrane Q-test and P values were used to determine the heterogeneity across studies. If heterogeneity was present (I2 ≥ 50% or P < 0.05), random-effect model was used to pool the results. Conversely, the fixed-effect model was applied for the analysis [13]. As for the acquisition of hazard ratios (HRs) of survival, the data were directly extracted from original articles. If not applicable, the data were calculated by using Engauge Digitizer version 4.1 (http://digitizer.sourceforge.net/) from Kaplan-Meier curves [14]. The publication bias was evaluated utilizing funnel plot, and P < 0.05 was considered as the existence of publication bias.

RESULTS

Characteristics of included studies

As shown in Figure 1, 157 articles were found according to the search strategy and then 115 duplicates are removed. Subsequently, 18 records without full-text were excluded. After reading the abstracts and full-texts of the remaining 24 articles, 15 records not conforming to the inclusion criteria were further excluded. Eventually, 9 studies [15–23] involving a total of 841 patients met the inclusion criteria. All included studies came from China, in which six different types of cancers were detected, with two cases of gastric cancer, two cases of colorectal cancer, one case of hepatocellular carcinoma, two cases of glioma, one case of non-small cell lung cancer and one case of epithelial ovarian cancer. The expression level of ZFAS1 was determined in collected tumor tissues and adjacent normal tissues by using qRT-PCR. The cut-off values for ZFAS1 expression included median and fold change. Each study was evaluated to be of high quality (≧ 6). The characteristics of the included studies were presented in Table 1.

Figure 1. Flow chart of the study search and selection.

Figure 1

Open in a new tab

Table 1. Characteristics of studies included in this meta-analysis.

First author Year Country Cancer type Total cases ZFAS1 expression Detection method Outcome measures Cut-off (high/low) Quality score
High Low
Li T 2015 China HCC 113 57 56 qRT-PCR OS, RFS median 8
Fang C 2016 China CRC 73 36 37 qRT-PCR N/A median 7
Nie F 2016 China GC 54 27 27 qRT-PCR OS, RFS median 8
Tian FM 2016 China NSCLC 173 85 88 qRT-PCR OS N/A 7
Wang W 2016 China CRC 159 79 80 qRT-PCR OS, RFS median 6
Gao K 2017 China glioma 46 23 23 qRT-PCR OS median 6
Lv QL 2017 China glioma 69 27 42 qRT-PCR OS N/A 8
Pan L 2017 China GC 94 58 36 qRT-PCR N/A fold ≧2.0 6
Xia B 2017 China EOC 60 30 30 qRT-PCR OS median 8
Open in a new tab

HCC: hepatocellular carcinoma; CRC: colorectal cancer; GC: gastric cancer; NSCLC: non-small cell lung cancer; EOC: epithelial ovarian cancer; qRT-PCR: quantitative real-time reverse transcription polymerase chain reaction; OS: overall survival; RFS: recurrence-free survival.

Association between ZFAS1 expression and overall survival (OS)

A total of seven studies reported the correlation between ZFAS1 expression and OS. Because of no statistical heterogeneity (P = 0.54, I2 = 0.0%), the fixed-effects model was chosen to estimate the pooled HRs and 95% CIs. The HR of the high ZFAS1 expression group versus low ZFAS1 expression group was 2.13 (95% CI = 1.71–2.65, P < 0.001, Figure 2). In other words, compared with low ZFAS1 expression group, high ZFAS1 expression group presented a statistically significant shorter OS, which implied that increased ZFAS1 expression was significantly associated with poor OS.

Figure 2. Forest plot of HRs for the association between ZFAS1 expression and OS in cancer patients.

Figure 2

Open in a new tab

As shown in Table 1, six different types of cancer (gastric cancer, colorectal cancer, hepatocellular carcinoma, glioma, non-small cell lung cancer and epithelial ovarian cancer) were included in this meta-analysis. Hence, we classified these studies into four subgroups (digestive system, nervous system, respiratory system and reproductive system) based on cancer types. As no significant heterogeneity among studies in different subgroups was detected, we used fixed-effects model to complete the synthesis of data. The results of subgroup analysis demonstrated that the HRs of the high ZFAS1 expression group versus the low ZFAS1 expression group in digestive system cancers, nervous system cancers, respiratory system cancers and reproductive system cancers were 1.88 (95% CI = 1.30–2.73, P < 0.001), 2.21 (95% CI = 1.43–3.42, P < 0.001), 2.76 (95% CI = 1.85–4.12, P < 0.001) and 1.40 (95% CI = 0.71–2.76, P = 0.33), respectively (Table 2 and Figure 3). Our data suggested that increased ZFAS1 expression in digestive system cancers, nervous system cancers and respiratory system cancers was statistically associated with shorter OS, whereas there was no significant difference of OS between high ZFAS1 expression group and low ZFAS1 expression group in reproductive system cancers (Table 2 and Figure 3).

Table 2. Subgroup meta-analysis of pooled HRs for OS.

Categories Studies (n) Total cases Fixed-effects model Heterogeneity
HR (95% CI) for OS P-value I2 (%) Ph
[1] OS 7 674 2.13 (1.71–2.65) < 0.001 0 0.54
[2] Cancer type
1) Digestive system 3 326 1.88 (1.30–2.73) < 0.001 0 0.77
2) Nervous system 2 115 2.21 (1.43–3.42) < 0.001 0 0.32
3) Respiratory system 1 173 2.76 (1.85–4.12) < 0.001 N/A N/A
4) Reproductive system 1 60 1.40 (0.71–2.76) 0.33 N/A N/A
[3] Cut-off (high/low)
Median 5 432 1.91 (1.41–2.58) < 0.001 0 0.60
Others 2 242 2.41 (1.75–3.31) < 0.001 16 0.28
[4] Sample sizes
> 100 3 445 2.25 (1.67–3.03) < 0.001 17 0.30
≤ 100 4 229 2.00 (1.45–2.76) < 0.001 0 0.50
[5] Duration of follow-up
≤ 40 months 2 167 1.89 (1.19–3.00) 0.007 0 0.47
> 40 months 5 507 2.21 (1.72–2.83) < 0.001 4 0.39
Open in a new tab

Figure 3. Forest plot of HRs for the association between ZFAS1 expression and OS in subgroup analysis based on different cancer types.

Figure 3

Open in a new tab

In addition, we conducted a series of subgroup meta-analysis based on cut-off (high/low), sample sizes and duration of follow-up. Since the heterogeneity among studies in all subgroups did not present statistically significant, the fixed-effects model was adopted to calculate the pooled HR and 95% CI. The results revealed that increased ZFAS1 expression was significantly associated with poor OS in all subgroup meta-analysis (Table 2 and Figures 4, 5 and 6).

Figure 4. Forest plot of HRs for the association between ZFAS1 expression and OS in subgroup analysis based on cut-off (high/low).

Figure 4

Open in a new tab

Figure 5. Forest plot of HRs for the association between ZFAS1 expression and OS in subgroup analysis based on sample sizes.

Figure 5

Open in a new tab

Figure 6. Forest plot of HRs for the association between ZFAS1 expression and OS in subgroup analysis based on duration of follow-up.

Figure 6

Open in a new tab

Association between ZFAS1 expression and recurrence-free survival (RFS)

A total of three studies described the association between ZFAS1 expression and RFS. Due to no statistically significant heterogeneity (P = 0.88, I2 = 0.0%), the fixed-effects model was adopted to calculate the pooled HR with corresponding 95% CI. Our results indicated that RFS was significantly shorter in high ZFAS1 expression group compared with that in low ZFAS1 expression group (HR = 2.00, 95% CI = 1.45–2.77, P < 0.001, Figure 7).

Figure 7. Forest plot of HRs for the association between ZFAS1 expression and RFS in cancer patients.

Figure 7

Open in a new tab

Association between ZFAS1 expression and clinicopathological parameters

We collected all the clinicopathological data from these eligible studies to perform further meta-analysis for the correlation between ZFAS1 expression and clinicopathological parameters. As presented in Table 3, increased ZFAS1 expression was significantly associated with vascular invasion (OR = 2.26, 95% CI = 1.36–3.78, P = 0.002, Supplementary Figure 1), lymph node metastasis (OR = 2.98, 95% CI = 2.12–4.19, P < 0.001, Supplementary Figure 2) and advanced TNM stage (OR = 3.00, 95% CI = 2.18–4.12, P < 0.001, Supplementary Figure 3). Conversely, no statistical correlation was observed between ZFAS1 expression with gender (P = 0.91, Supplementary Figure 4) and tumor size (P = 0.05, Supplementary Figure 5). Due to insufficient data for other clinicopathological parameters (such as age, distant metastasis, tumor differentiation), the association between ZFAS1 expression and these clinicopathological parameters were not evaluated for the meta-analysis.

Table 3. Meta-analysis of the association between ZFAS1 expression and clinicopathological parameters.

Clinicopathological parameters Studies (n) Total cases OR (95% CI) P-value Heterogeneity
I2 (%) Ph Model
Gender (Male vs. Female) 7 701 0.98 (0.73–1.33) 0.91 15 0.32 Fixed
Tumor size (≥ 5 cm vs. < 5 cm) 5 539 1.41 (1.00–1.99) 0.05 24 0.26 Fixed
Vascular invasion (Yes vs. No) 3 280 2.26 (1.36–3.78) 0.002 0 0.52 Fixed
Lymph node metastasis (Yes vs. No) 6 613 2.98 (2.12–4.19) < 0.001 11 0.35 Fixed
TNM stage ( III–IV vs. I–II) 7 679 3.00 (2.18–4.12) < 0.001 2 0.41 Fixed
Open in a new tab

Publication bias and sensitivity analysis

Funnel plot analysis was performed to evaluate publication bias for the association between ZFAS1 expression and OS in cancer patients.in the study. The results showed that no obvious publication bias was observed in the included studies for this meta-analysis (Supplementary Figure 6). Sensitivity analysis was conducted to determine whether the individual study exerted influence on the overall results. Our data suggested that removing any of the included studies had no significant influence on the results (Supplementary Figure 7), which demonstrated that our results were considerably reasonable and reliable.

DISCUSSION

Previous studies reported that lncRNAs played crucial roles in the process of gene expression and their dysregulation were involved in the tumorigenesis and progression of malignant tumors [24, 25]. Notably, antisense lncRNAs (aslncRNAs), oriented in antisense direction with respect to a protein coding loci, also serve as key regulators of genes located on the opposite strand [26]. Growing number of studies identified that aslncRNAs functioned as promoters or enhancers of cancer-related gene expressions in the complex network of signaling pathways in different cancer cell [27, 28].

LncRNA zinc finger antisense 1 (ZFAS1) locus is host to three C/D-box small nucleolar RNAs (snoRNAs), and its transcription starts from the antisense strand near the 5′end of the protein-coding gene Znfx1 [29]. Numerous studies reported that the expression levels of ZFAS1 in tumor tissues were dramatically higher than that in adjacent normal tissues [16, 18]. Additionally, the depletion of ZFAS1 could substantially suppress the proliferation, invasion and migration of cancer cells, while the overexpression of ZFAS1 could markedly promote the tumorigenesis and metastasis [19]. As for the specific molecular mechanism, Li, T et al. found that ZFAS1 increased ZEB1, MMP14 and MMP16 expression and promoted HCC metastasis by sponging miR-150 and inhibiting its function [23]. Furthermore, silenced ZFAS1 could impair migration and invasion by inhibiting the epithelial–mesenchymal transition through reducing the expression of MMP2, MMP9, N-cadherin, Integrin β1, ZEB1, Twist, and Snail as well as increasing E-cadherin level in glioma [21]. Besides, Thorenoor, N et al. identified ZFAS1 as an oncogene via destabilization of p53 and through interaction with CDK1/cyclin B1 complex leading to cell cycle progression and inhibition of cell apoptosis in CRC cells [10].

This meta-analysis was to investigate the prognostic role of lncRNA ZFAS1 in cancer patients. Based on the analysis results, we found that increased ZFAS1 expression was significantly associated with poor OS in cancer patients. Further subgroup meta-analysis demonstrated that ZFAS1 could be a reliable prognostic biomarker for digestive system cancers, nervous system cancers and respiratory system cancers. Likewise, patients with high ZFAS1 expression presented shorter RFS than those with low ZFAS1 expression. Besides, we conducted the meta-analysis for the association between ZFAS1 expression and clinicopathological parameters. The results showed that patients with high ZFAS1 expression had a higher risk of vascular invasion and they suffered higher possibility of developing lymph node metastasis and advanced TNM stage (III–IV), indicating that increased ZFAS1 expression may be closely related to advanced characteristics of cancer.

However, there were several limitations that should be considered in our analysis. To begin with, all studies came from China, which made the included cases could not represent all cancer patients to some extent. Next, the cut-off value for dividing patients into high and low ZFAS1 expression groups was not consistent across studies. Finally, no prospective study was included for further investigation. Therefore, large-scale, multicenter and high-quality studies are supposed to confirm our analysis results in the future.

In conclusion, this meta-analysis suggested that lncRNA ZFAS1 might serve as a prognostic biomarker for cancer patients. Furthermore, increased ZFAS1 expression may be closely related to advanced characteristics of cancer. Nonetheless, due to the limitations in our analysis, large-scale, multicenter and high-quality studies are required to support our results in the future.

SUPPLEMENTARY MATERIALS FIGURES

Footnotes

CONFLICTS OF INTEREST

The authors declare no conflicts of interests.

REFERENCES

  • 1.Bray F, Ren JS, Masuyer E, Ferlay J. Global estimates of cancer prevalence for 27 sites in the adult population in 2008. International journal of cancer. 2013;132:1133–1145. doi: 10.1002/ijc.27711. [DOI] [PubMed] [Google Scholar]
  • 2.Gonzalez CA, Agudo A. Carcinogenesis, prevention and early detection of gastric cancer: where we are and where we should go. International journal of cancer. 2012;130:745–753. doi: 10.1002/ijc.26430. [DOI] [PubMed] [Google Scholar]
  • 3.Shi X, Sun M, Liu H, Yao Y, Song Y. Long non-coding RNAs: a new frontier in the study of human diseases. Cancer letters. 2013;339:159–166. doi: 10.1016/j.canlet.2013.06.013. [DOI] [PubMed] [Google Scholar]
  • 4.Huang S, He X. The role of microRNAs in liver cancer progression. British journal of cancer. 2011;104:235–240. doi: 10.1038/sj.bjc.6606010. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Mannoor K, Liao J, Jiang F. Small nucleolar RNAs in cancer. Biochimica et biophysica acta. 2012;1826:121–128. doi: 10.1016/j.bbcan.2012.03.005. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Huang JL, Zheng L, Hu YW, Wang Q. Characteristics of long non-coding RNA and its relation to hepatocellular carcinoma. Carcinogenesis. 2014;35:507–514. doi: 10.1093/carcin/bgt405. [DOI] [PubMed] [Google Scholar]
  • 7.Fatica A, Bozzoni I. Long non-coding RNAs: new players in cell differentiation and development. Nature reviews Genetics. 2014;15:7–21. doi: 10.1038/nrg3606. [DOI] [PubMed] [Google Scholar]
  • 8.Liu R, Zeng Y, Zhou CF, Wang Y, Li X, Liu ZQ, Chen XP, Zhang W, Zhou HH. Long noncoding RNA expression signature to predict platinum-based chemotherapeutic sensitivity of ovarian cancer patients. Scientific reports. 2017;7:18. doi: 10.1038/s41598-017-00050-w. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Zhou H, Wang F, Chen H, Tan Q, Qiu S, Chen S, Jing W, Yu M, Liang C, Ye S, Tu J. Increased expression of long-noncoding RNA ZFAS1 is associated with epithelial-mesenchymal transition of gastric cancer. Aging (Albany NY) 2016;8:2023–2038. doi: 10.18632/aging.101048. https://doi.org/10.18632/aging.101048. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Thorenoor N, Faltejskova-Vychytilova P, Hombach S, Mlcochova J, Kretz M, Svoboda M, Slaby O. Long non-coding RNA ZFAS1 interacts with CDK1 and is involved in p53-dependent cell cycle control and apoptosis in colorectal cancer. Oncotarget. 2016;7:622–637. doi: 10.18632/oncotarget.5807. https://doi.org/10.18632/oncotarget.5807. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. European journal of epidemiology. 2010;25:603–605. doi: 10.1007/s10654-010-9491-z. [DOI] [PubMed] [Google Scholar]
  • 12.Singletary SE, Allred C, Ashley P, Bassett LW, Berry D, Bland KI, Borgen PI, Clark GM, Edge SB, Hayes DF, Hughes LL, Hutter RV, Morrow M, et al. Staging system for breast cancer: revisions for the 6th edition of the AJCC Cancer Staging Manual. The Surgical clinics of North America. 2003;83:803–819. doi: 10.1016/S0039-6109(03)00034-3. [DOI] [PubMed] [Google Scholar]
  • 13.Egger M, Smith GD, Phillips AN. Meta-analysis: principles and procedures. BMJ (Clinical research ed) 1997;315:1533–1537. doi: 10.1136/bmj.315.7121.1533. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Liu FT, Xue QZ, Zhu PQ, Luo HL, Zhang Y, Hao T. Long noncoding RNA AFAP1-AS1, a potential novel biomarker to predict the clinical outcome of cancer patients: a meta-analysis. OncoTargets and therapy. 2016;9:4247–4254. doi: 10.2147/OTT.S107188. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Li T, Xie J, Shen C, Cheng D, Shi Y, Wu Z, Deng X, Chen H, Shen B, Peng C, Li H, Zhan Q, Zhu Z. Amplification of Long Noncoding RNA ZFAS1 Promotes Metastasis in Hepatocellular Carcinoma. Cancer research. 2015;75:3181–3191. doi: 10.1158/0008-5472.CAN-14-3721. [DOI] [PubMed] [Google Scholar]
  • 16.Fang C, Zan J, Yue B, Liu C, He C, Yan D. Long Noncoding RNA ZFAS1 promotes the progression of colonic cancer by modulating ZEB1 expression. Journal of gastroenterology and hepatology. 2016 doi: 10.1111/jgh.13646. [DOI] [PubMed] [Google Scholar]
  • 17.Nie F, Yu X, Huang M, Wang Y, Xie M, Ma H, Wang Z, De W, Sun M. Long noncoding RNA ZFAS1 promotes gastric cancer cells proliferation by epigenetically repressing KLF2 and NKD2 expression. Oncotarget. 2016;8:38227–38238. doi: 10.18632/oncotarget.9611. https://doi.org/10.18632/oncotarget.9611. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Tian FM, Meng FQ, Wang XB. Overexpression of long-noncoding RNA ZFAS1 decreases survival in human NSCLC patients. European review for medical and pharmacological sciences. 2016;20:5126–5131. [PubMed] [Google Scholar]
  • 19.Wang W, Xing C. Upregulation of long noncoding RNA ZFAS1 predicts poor prognosis and prompts invasion and metastasis in colorectal cancer. Pathology, research and practice. 2016;212:690–695. doi: 10.1016/j.prp.2016.05.003. [DOI] [PubMed] [Google Scholar]
  • 20.Gao K, Ji Z, She K, Yang Q, Shao L. Long non-coding RNA ZFAS1 is an unfavourable prognostic factor and promotes glioma cell progression by activation of the Notch signaling pathway. Biomedicine & pharmacotherapy. 2017;87:555–560. doi: 10.1016/j.biopha.2017.01.014. [DOI] [PubMed] [Google Scholar]
  • 21.Lv QL, Chen SH, Zhang X, Sun B, Hu L, Qu Q, Huang YT, Wang GH, Liu YL, Zhang YY, Zhou HH. Upregulation of long noncoding RNA zinc finger antisense 1 enhances epithelial-mesenchymal transition in vitro and predicts poor prognosis in glioma. Tumour biology. 2017;39:1010428317695022. doi: 10.1177/1010428317695022. [DOI] [PubMed] [Google Scholar]
  • 22.Pan L, Liang W, Fu M, Huang ZH, Li X, Zhang W, Zhang P, Qian H, Jiang PC, Xu WR, Zhang X. Exosomes-mediated transfer of long noncoding RNA ZFAS1 promotes gastric cancer progression. Journal of cancer research and clinical oncology. 2017 doi: 10.1007/s00432-017-2361-2. [DOI] [PubMed] [Google Scholar]
  • 23.Xia B, Hou Y, Chen H, Yang S, Liu T, Lin M, Lou G. Long non-coding RNA ZFAS1 interacts with miR-150-5p to regulate Sp1 expression and ovarian cancer cell malignancy. Oncotarget. 2017;8:19534–19546. doi: 10.18632/oncotarget.14663. https://doi.org/10.18632/oncotarget.14663. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Lan T, Chang L, Wu L, Yuan Y. Downregulation of ZEB2-AS1 decreased tumor growth and metastasis in hepatocellular carcinoma. Molecular medicine reports. 2016;14:4606–4612. doi: 10.3892/mmr.2016.5836. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Lan T, Ma W, Hong Z, Wu L, Chen X, Yuan Y. Long non-coding RNA small nucleolar RNA host gene 12 (SNHG12) promotes tumorigenesis and metastasis by targeting miR-199a/b-5p in hepatocellular carcinoma. Journal of experimental & clinical cancer research. 2017;36:11. doi: 10.1186/s13046-016-0486-9. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Nolasco S, Bellido J, Goncalves J, Tavares A, Zabala JC, Soares H. The expression of tubulin cofactor A (TBCA) is regulated by a noncoding antisense Tbca RNA during testis maturation. PloS one. 2012;7:e42536. doi: 10.1371/journal.pone.0042536. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Li J, Lian Y, Yan C, Cai Z, Ding J, Ma Z, Peng P, Wang K. Long non-coding RNA FOXP4-AS1 is an unfavourable prognostic factor and regulates proliferation and apoptosis in colorectal cancer. Cell proliferation. 2017;50 doi: 10.1111/cpr.12312. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Liu YW, Xia R, Lu K, Xie M, Yang F, Sun M, De W, Wang C, Ji G. LincRNAFEZF1-AS1 represses p21 expression to promote gastric cancer proliferation through LSD1-Mediated H3K4me2 demethylation. Molecular cancer. 2017;16:39. doi: 10.1186/s12943-017-0588-9. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Askarian-Amiri ME, Crawford J, French JD, Smart CE, Smith MA, Clark MB, Ru K, Mercer TR, Thompson ER, Lakhani SR, Vargas AC, Campbell IG, Brown MA, et al. SNORD-host RNA Zfas1 is a regulator of mammary development and a potential marker for breast cancer. Vol. 17. RNA; New York, NY: 2011. pp. 878–891. [DOI] [PMC free article] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

oncotarget-08-100490-s001.pdf (2.3MB, pdf)

Articles from Oncotarget are provided here courtesy of Impact Journals, LLC

RESOURCES